title: Vaccination with liposomal leishmanial antigens adjuvanted with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) confers long-term protection against visceral leishmaniasis through a human administrable route.
abstract: The development of a long-term protective subunit vaccine against visceral leishmaniasis depends on antigens and adjuvants that can induce an appropriate immune response. The immunization of leishmanial antigens alone shows limited efficacy in the absence of an appropriate adjuvant. Earlier we demonstrated sustained protection against Leishmania donovani with leishmanial antigens entrapped in cationic liposomes through an intraperitoneal route. However, this route is not applicable for human administration. Herein, we therefore evaluated the immune response and protection induced by liposomal soluble leishmanial antigen (SLA) formulated with monophosphoryl lipid-trehalose dicorynomycolate (MPL-TDM) through a subcutaneous route. Subcutaneous immunization of BALB/c mice with SLA entrapped in liposomes or with MPL-TDM elicited partial protection against experimental visceral leishmaniasis. In contrast, liposomal SLA adjuvanted with MPL-TDM induced significantly higher levels of protection in liver and spleen in BALB/c mice challenged 10 days post-vaccination. Protection conferred by this formulation was sustained up to 12 weeks of immunization, and infection was controlled for at least 4 months of the challenge, similar to liposomal SLA immunization administered intraperitoneally. An analysis of cellular immune responses of liposomal SLA + MPL-TDM immunized mice demonstrated the induction of IFN-γ and IgG2a antibody production not only 10 days or 12 weeks post-vaccination but also 4 months after the challenge infection and a down regulation of IL-4 production after infection. Moreover, long-term immunity elicited by this formulation was associated with IFN-γ production also by CD8⁺ T cells. Taken together, our results suggest that liposomal SLA + MPL-TDM represent a good vaccine formulation for the induction of durable protection against L. donovani through a human administrable route.
authors: Infectious Diseases and Immunology Division, Indian Institute of Chemical Biology, Jadavpur, Kolkata-700032, India.
authors: Rajesh
authors: R
authors: Ravindran
authors: Mithun
authors: M
authors: Maji
authors: Nahid
authors: N
authors: Ali
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage* / Q000737:chemistry; D000818:Animals; D000953:Antigens, Protozoan / Q000008:administration & dosage* / Q000737:chemistry / Q000302:isolation & purification / Q000627:therapeutic use; D002478:Cells, Cultured; D055598:Chemical Phenomena; D003311:Cord Factors / Q000008:administration & dosage* / Q000737:chemistry; D007110:Immunity, Active; D007111:Immunity, Cellular; D007156:Immunologic Memory; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000378:metabolism; D015847:Interleukin-4 / Q000378:metabolism; D007893:Leishmania donovani / Q000276:immunology* / Q000378:metabolism; D054332:Leishmaniasis Vaccines / Q000008:administration & dosage* / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D007898:Leishmaniasis, Visceral / Q000276:immunology / Q000469:parasitology / Q000517:prevention & control*; D008050:Lipid A / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000737:chemistry; D008081:Liposomes; D008099:Liver / Q000469:parasitology; D051379:Mice; D008807:Mice, Inbred BALB C; D010743:Phospholipids / Q000008:administration & dosage* / Q000737:chemistry; D013047:Specific Pathogen-Free Organisms; D013154:Spleen / Q000276:immunology / Q000378:metabolism / Q000469:parasitology / Q000473:pathology
chemical_list: D000276:Adjuvants, Immunologic; D000953:Antigens, Protozoan; D003311:Cord Factors; D054332:Leishmaniasis Vaccines; D008050:Lipid A; D008081:Liposomes; D010743:Phospholipids; D015847:Interleukin-4; D007371:Interferon-gamma; C043399:6,6'-dicorynomycolyl trehalose